Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge

The ongoing SARS-CoV-2 pandemic represents a brutal reminder of the continual threat of mucosal infectious diseases. Mucosal immunity may provide robust protection at the predominant sites of SARS-CoV-2 infection. However, it remains unclear whether respiratory mucosal administration of DNA vaccines...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Si, Li, Entao, Zhao, Gan, Tang, Jie, Zuo, Qianfei, Cai, Larry, Xu, Chuanfei, Sui, Cheng, Ou, Yangxue, Liu, Chang, Li, Haibo, Ding, Yuan, Li, Chao, Lu, Dongshui, Zhang, Weijun, Luo, Ping, Cheng, Ping, Gao, Yuwei, Tu, Changchun, Pitard, Bruno, Rosenecker, Joseph, Wang, Bin, Liu, Yan, Zou, Quanming, Guan, Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673044/
https://www.ncbi.nlm.nih.gov/pubmed/36436305
http://dx.doi.org/10.1016/j.biomaterials.2022.121907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673044/
https://www.ncbi.nlm.nih.gov/pubmed/36436305
http://dx.doi.org/10.1016/j.biomaterials.2022.121907

Ejemplares similares